In this study, we used CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) technologies to regulate the transcription of ITGB5, TIMP1, and TMEM176B in prostate cancer cells. Here, TIMP1 is linked to prostate carcinoma.